Exagen Inc. Common Stock XGN
i
Market dataready · fetched 2026-11-04T09:03:56.292Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2027-01-15
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-04T09:00:07.667511153Z
FundamentalsSEC EDGAR · ready · as of 2026-06-30 · fetched 2026-11-04T09:03:55.464118+00:00
Exagen Inc. Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 5.46 | 206.5% | 47.0% | |||
| 25Δ | 6.14 | 179.4% | 39.2% | |||
| 30Δ | 6.83 | 152.4% | 31.3% | |||
| 35Δ | 7.51 | 126.0% | 23.7% | |||
| 40Δ | 12.86 | 169.0% | 77.5% | 7.83 | 118.2% | 21.0% |
| 45Δ | 11.21 | 155.8% | 58.2% | 8.14 | 110.3% | 18.4% |
| 50Δ | 9.86 | 145.3% | 43.0% | 8.46 | 102.5% | 15.7% |
| 55Δ | 9.09 | 140.1% | 35.4% | 8.77 | 94.7% | 13.1% |
| 60Δ | 8.31 | 134.9% | 27.8% | 9.09 | 86.8% | 10.4% |
| 65Δ | 7.54 | 129.8% | 20.3% | 9.41 | 79.0% | 7.8% |
| 70Δ | 6.85 | 142.7% | 17.6% | 9.72 | 71.2% | 5.2% |
| 75Δ | 6.18 | 156.4% | 15.2% | |||
| 80Δ | 5.50 | 170.2% | 12.8% | |||
20Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 5.46
- IV
- 206.5%
- B/E move
- 47.0%
25Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 6.14
- IV
- 179.4%
- B/E move
- 39.2%
30Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 6.83
- IV
- 152.4%
- B/E move
- 31.3%
35Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 7.51
- IV
- 126.0%
- B/E move
- 23.7%
40Δ
- Pseudo strike
- 12.86
- IV
- 169.0%
- B/E move
- 77.5%
- Pseudo strike
- 7.83
- IV
- 118.2%
- B/E move
- 21.0%
45Δ
- Pseudo strike
- 11.21
- IV
- 155.8%
- B/E move
- 58.2%
- Pseudo strike
- 8.14
- IV
- 110.3%
- B/E move
- 18.4%
50Δ
- Pseudo strike
- 9.86
- IV
- 145.3%
- B/E move
- 43.0%
- Pseudo strike
- 8.46
- IV
- 102.5%
- B/E move
- 15.7%
55Δ
- Pseudo strike
- 9.09
- IV
- 140.1%
- B/E move
- 35.4%
- Pseudo strike
- 8.77
- IV
- 94.7%
- B/E move
- 13.1%
60Δ
- Pseudo strike
- 8.31
- IV
- 134.9%
- B/E move
- 27.8%
- Pseudo strike
- 9.09
- IV
- 86.8%
- B/E move
- 10.4%
65Δ
- Pseudo strike
- 7.54
- IV
- 129.8%
- B/E move
- 20.3%
- Pseudo strike
- 9.41
- IV
- 79.0%
- B/E move
- 7.8%
70Δ
- Pseudo strike
- 6.85
- IV
- 142.7%
- B/E move
- 17.6%
- Pseudo strike
- 9.72
- IV
- 71.2%
- B/E move
- 5.2%
75Δ
- Pseudo strike
- 6.18
- IV
- 156.4%
- B/E move
- 15.2%
- Pseudo strike
- IV
- B/E move
80Δ
- Pseudo strike
- 5.50
- IV
- 170.2%
- B/E move
- 12.8%
- Pseudo strike
- IV
- B/E move
Options history
Table
| Date | IV (%) |
|---|---|
| 118.44% | |
| 116.51% | |
| 115.25% | |
| 137.38% | |
| 127.26% | |
| 118.39% | |
| 111.26% | |
| 126.39% |
Diagnostics & Research
A
Agilent Technologies, Inc. is an American analytical instrumentation development and manufacturing company that offers its products and services to markets worldwide. Its global…
More →ADPT
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company is…
More →BLLN
BillionToOne, Inc., a precision diagnostics company, quantifies biology to create molecular diagnostics. The company is headquartered in Menlo Park, California.
More →CDNA
CareDx, Inc. discovers, develops and markets diagnostic solutions for transplant patients and caregivers globally. The company is headquartered in South San Francisco, California.
More →CRL
Charles River Laboratories International, Inc., is an American pharmaceutical company specializing in a variety of preclinical and clinical laboratory, gene therapy and cell…
More →CSTL
Description unavailable
More →